Everything below concerns melanogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
On sale from 3 July 2007. The list was compiled through a combination of suggestions from Edge readers, Edge staff and additional "industry experts". Each game in the list had a retrospective article, a full-page illustration, and a sidebar listing readers' comments. In addition, the volume contained reprints of the magazine's previous "Top 100" lists from 2000 (issue 80) and 2003 (issue 128). The top 10 of Edge Presents The 100 Best Videogames were: The Legend of Zelda: Ocarina of Time Resident Evil 4 Super Mario 64 Half-Life 2 Super Mario World The Legend of Zelda: A Link to the Past Halo: Combat Evolved Final Fantasy XII Tetris Super Metroid An Edge Special Edition - "the 100 greatest videogames" (2015)
In September 2026, a UN-commissioned fact-finding mission panel found "reasonable grounds" to believe that the United States had committed war crimes during military strikes in Iran during the 2026 Iran war. The report highlighted two 28 February strikes that killed at least 178 civilians. U.S. president Donald Trump's threats to completely destroy Iranian power plants and other essential infrastructure during the 2026 Iran war have been widely condemned by human rights organizations, legal experts, and lawmakers as potential war crimes. The report published by the Independent International Fact-Finding Mission on Iran detailed two specific U.S. military operations on the first day of the 2026 Iran war that it determined constituted indiscriminate attacks on civilian infrastructure, the Minab School Bombing, where a U.S. Tomahawk missile strike targeted the Shajareh Tayyebeh Primary School in the southern city of Minab. The attack killed more than 150 people, including approximately 120 children. The UN mission concluded that the school was the intended point of impact rather than collateral damage, as well as the Lamerd Sports Complex Strike, where a separate U.S. airstrike utilized precision strike missiles to disperse tungsten pellets over a clearly identifiable sports complex and residential area in Lamerd. The attack resulted in the deaths of 22 civilian men and women. The Trump administration firmly rejected the allegations. White House spokeswoman Anna Kelly dismissed the findings as "unserious nonsense," stating that the U.S.
=== Water footprint === One ton of hide or skin generally produces 20 to 80 m3 of waste water, including chromium levels of 100–400 mg/L, sulfide levels of 200–800 mg/L, high levels of fat and other solid wastes, and notable pathogen contamination. Producers often add pesticides to protect hides during transport. With solid wastes representing up to 70% of the wet weight of the original hides, the tanning process represents a considerable strain on water treatment installations.
Their feature documentary Kumu Hina, about transgender native Hawaiian teacher and cultural icon Hinaleimoana Wong-Kalu, was supported by ITVS, Pacific Islanders in Communications and the Ford Foundation and won the GLAAD Media Award for Outstanding Documentary and the Independent Lens Audience Award on PBS In 2017, Hamer and Wilson, with Hinaleimoana Wong-Kalu as producer, released Leitis in Waiting and Lady Eva, which documented the lives of transgender women in the conservative South Pacific Kingdom of Tonga. This was followed in 2019 by The Rogers, about transgender men in Samoa. These films became part of a campaign to decriminalize same-sex relationships across the Pacific. Hamer, Wilson and Wong-Kalu continued their collaboration in 2020 with the animated short film Kapaemahu, based on the hidden history of four stones on Waikiki Beach placed there as a tribute to four legendary mahu who first brought the healing arts from Tahiti to Hawaii. It premiered and won the Special Jury Prize at the Tribeca Film Festival and was shortlisted for an Oscar as Best Animated Short Film at the 93rd Academy Awards. The animated film was followed by a children's book published by Kokila, a PBS feature documentary, a multimedia exhibition at the Bishop Museum, permanent display at the Hawaiʻi Convention center, and inclusion in new interpretative signage at the Kapaemahu monument in Waikiki. The team's most recent film is Aikane, an animated short based on the Hawaiian term for intimate friends of the same sex.
Israel–Hezbollah conflict (2023–present): The Ministry of Defence announces that 700 British troops will be deployed to Cyprus in anticipation of an evacuation of British citizens from Lebanon. Starmer advises British nationals in Lebanon to "leave immediately" as tension between Hezbollah and Israel increases. 25 September – Petrol prices fall to their lowest level in three years, with the average price for a litre of unleaded costing about £1.35. 27 September Lexi Secker, a transgender woman who raped a woman on a night out prior to identifying as a woman, is jailed for six and a half years with the sentence to be served in a male prison. Two 13-year-old boys are detained for at least eight and a half years for the 2023 murder of Shawn Seesahai in Wolverhampton, carried out using a machete when they were 12. They are the youngest killers to be sentenced since the murder of James Bulger in 1993. Sir Brian May resigns as vice president of the Royal Society for the Prevention of Cruelty to Animals (RSPCA) over what he describes as "damning evidence" of animal welfare failings related to its food certification label. 28 September – Labour MP Rosie Duffield quits the party over what she describes as leader Keir Starmer's "cruel" policies and "staggering hypocrisy" over his acceptance of gifts. In her resignation letter to Starmer she says, "The sleaze, nepotism and apparent avarice are off the scale.
Sources: en.wikipedia.org
== Early life and career == Cantelmo was a high school valedictorian. He graduated from Yale University with a degree in molecular biophysics and biochemistry. He worked for about 35 years in the pharmaceutical industry, specializing in high-performance liquid chromatography (HPLC). According to his own accounts and those of family members, he ran three HPLC companies. The last of these was GL Sciences. He left that position prior to the events of 2019. GL Sciences has stated it has no association with Cantelmoism or the use of illegal drugs. Cantelmo had a history of mental health difficulties and prior suicide attempts. He had also used other substances, including mescaline, LSD, and methamphetamine, at earlier points in his life.
In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own. In 2019, the FDA rejected a Serepta Duchenne muscular dystrophy drug before reversing course 3 months later. The company opened a new Genetic Therapies Center of Excellence in Columbus, Ohio in October, 2021 in order to dramatically advance research into therapeutics for several muscular dystrophies that had begun at Nationwide Children's Hospital several years earlier. As of 2022, there are three FDA-approved DMD drugs in Sarepta Therapeutics' portfolio. In January 2023, Sarepta partnered with Catalent to manufacture delandistrogene moxeparvovec (SRP-9001). In June 2023, the FDA approved Sarepta Therapeutics’ fourth therapy, delandistrogene moxeparvovec-rokl, the first gene therapy to treat Duchenne muscular dystrophy (DMD). The product was approved under the accelerated approval pathway for 4-5 year olds with a confirmed DMD diagnosis. Accelerated approval requires that the product be studied further to verify its clinical benefit. In July 2025, Sarepta announced plans to lay off 500 employees, about 36% of its workforce, following the deaths of two patients linked to its Duchenne muscular dystrophy gene therapy, ELEVIDYS.
integral monotopic protein Any of a class of integral membrane proteins which are permanently attached to one side of the cell membrane by any means but which do not completely span the membrane. Contrast integral polytopic protein.
https://www.bioinformatics.nl/tools/pam.html Website that calculates a PAM matrix for any level. https://ftp.ncbi.nih.gov/repository/blocks/unix/blosum/MDM/ for PAM matrices from 1992 (PAM80, 120, 160, 210, 250 calculated using the "pam" program and PAM250 from Gonnet, Cohen & Benner 1992) https://www.ncbi.nlm.nih.gov/IEB/ToolBox/C_DOC/lxr/source/data/ for PAM30, PAM70, and PAM250 in the NCBI C Toolkit. https://github.com/ncbi/ncbi-cxx-toolkit-public/tree/main/src/util/tables for the same tables in the NCBI C++ Toolkit. https://ftp.ncbi.nih.gov/blast/matrices/ NCBI "Bonus Matrices" for BLAST, includes PAM10–500 and many other matrices. Also includes the source code for the "pam" program, which multiplies the data from Dayhoff to extrapolate other PAM values. Later derivations of PAM-type matrices:
Sources: en.wikipedia.org
=== Costs === At between US$6,000 and $10,000 for a typical treatment, BMPs can be costly compared with other techniques such as bone grafting. However, this cost is often far less than the costs required with orthopaedic revision in multiple surgeries. While there is little debate that rhBMPs are successful clinically, there is controversy about their use. It is common for orthopedic surgeons to be paid for their contribution to the development of a new product, but some of the surgeons responsible for the original Medtronic-supported studies on the efficacy of rhBMP-2 have been accused of bias and conflict of interest. For example, one surgeon, a lead author on four of these research papers, did not disclose any financial ties while with the company on three of the papers; he was paid over $4 million by Medtronic. In another study, the lead author did not disclose any financial ties to Medtronic; he was paid at least $11 million by the company. In a series of 12 publications, the median financial ties of the authors to Medtronic were $12–16 million. In those studies that had more than 20 and 100 patients, one or more authors had financial ties of $1 million and $10 million, respectively. Early clinical trials using rhBMP-2 underreported adverse events associated with treatment. In the 13 original industry-sponsored publications related to safety, there were zero adverse events in 780 patients. It has since been revealed that potential complications can arise from the use including implant displacement, subsidence, infection, urogenital events, and retrograde ejaculation.
This unit is still in development phase at the time of writing but is significant as it has the potential to run much higher compression ratios than even other rotary valve engines due to a significant but undisclosed new cooling method of the combustion chamber and the ability to eliminate the throttle completely, making it vastly more economical at lower engine speeds, so it is claimed. A proven automotive rotary valve engine was developed by Ralph Ogden Watson of Auckland New Zealand, during 1989. Since its inception, the car with the rotary valve has covered many trouble-free miles and remains in use.
== Medicine and biotechnology == Aminopeptidase has been studied for use in treating hypertension, inflammation, and some cancers. Aminopeptidase A (APA) is implicated in blood pressure regulation by converting angiotensin II to angiotensin III. APA inhibitors are being explored as potential antihypertensive agents, offering a novel approach to managing hypertension. Aminopeptidase N (APN) has been associated with the pathogenesis of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Inhibitors of APN have demonstrated anti-inflammatory effects in animal models, positioning them as potential therapeutic agents for these conditions. Several aminopeptidases, including APN, APA, and leucine aminopeptidase (LAP), are overexpressed in various cancers. Their involvement in tumor growth, invasion, and angiogenesis makes them attractive targets for cancer therapy. Aminopeptidase inhibitors have shown promise in preclinical studies as potential anticancer agents.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.